125 related articles for article (PubMed ID: 35450352)
1. Novel RIPK1 Inhibitors for Treating Neurodegenerative, Autoimmune, and Inflammatory Diseases.
Sabnis RW
ACS Med Chem Lett; 2022 Apr; 13(4):524-525. PubMed ID: 35450352
[No Abstract] [Full Text] [Related]
2. Novel Fused Triazole Compounds as RIPK1 Inhibitors for Treating Neurodegenerative, Autoimmune, and Inflammatory Diseases.
Sabnis RW
ACS Med Chem Lett; 2024 Feb; 15(2):177-178. PubMed ID: 38352847
[TBL] [Abstract][Full Text] [Related]
3. Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target.
Mifflin L; Ofengeim D; Yuan J
Nat Rev Drug Discov; 2020 Aug; 19(8):553-571. PubMed ID: 32669658
[TBL] [Abstract][Full Text] [Related]
4. Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis.
Hou J; Ju J; Zhang Z; Zhao C; Li Z; Zheng J; Sheng T; Zhang H; Hu L; Yu X; Zhang W; Li Y; Wu M; Ma H; Zhang X; He S
Cell Death Dis; 2019 Jun; 10(7):493. PubMed ID: 31235688
[TBL] [Abstract][Full Text] [Related]
5. Novel insights into RIPK1 as a promising target for future Alzheimer's disease treatment.
Li S; Qu L; Wang X; Kong L
Pharmacol Ther; 2022 Mar; 231():107979. PubMed ID: 34480965
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and evaluation of potent RIPK1 inhibitors with in vivo anti-inflammatory activity.
Li Z; Hao Y; Yang C; Yang Q; Wu S; Ma H; Tian S; Lu H; Wang J; Yang T; He S; Zhang X
Eur J Med Chem; 2022 Jan; 228():114036. PubMed ID: 34906762
[TBL] [Abstract][Full Text] [Related]
7. Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patients.
Vissers MFJM; Heuberger JAAC; Groeneveld GJ; Oude Nijhuis J; De Deyn PP; Hadi S; Harris J; Tsai RM; Cruz-Herranz A; Huang F; Tong V; Erickson R; Zhu Y; Scearce-Levie K; Hsiao-Nakamoto J; Tang X; Chang M; Fox BM; Estrada AA; Pomponio RJ; Alonso-Alonso M; Zilberstein M; Atassi N; Troyer MD; Ho C
Clin Transl Sci; 2022 Aug; 15(8):2010-2023. PubMed ID: 35649245
[TBL] [Abstract][Full Text] [Related]
8. Microglial Dysfunction in Neurodegenerative Diseases via RIPK1 and ROS.
Wu Q; Zou C
Antioxidants (Basel); 2022 Nov; 11(11):. PubMed ID: 36358573
[TBL] [Abstract][Full Text] [Related]
9. Targeting RIPK1 kinase for modulating inflammation in human diseases.
Li W; Yuan J
Front Immunol; 2023; 14():1159743. PubMed ID: 36969188
[TBL] [Abstract][Full Text] [Related]
10. Harnessing Protein-Ligand Interaction Fingerprints to Predict New Scaffolds of RIPK1 Inhibitors.
Aniceto N; Marques V; Amaral JD; Serra PA; Moreira R; Rodrigues CMP; Guedes RC
Molecules; 2022 Jul; 27(15):. PubMed ID: 35897894
[TBL] [Abstract][Full Text] [Related]
11. The latest information on the RIPK1 post-translational modifications and functions.
Wang Q; Fan D; Xia Y; Ye Q; Xi X; Zhang G; Xiao C
Biomed Pharmacother; 2021 Oct; 142():112082. PubMed ID: 34449307
[TBL] [Abstract][Full Text] [Related]
12. Genetic Regulation of RIPK1 and Necroptosis.
Xu D; Zou C; Yuan J
Annu Rev Genet; 2021 Nov; 55():235-263. PubMed ID: 34813352
[TBL] [Abstract][Full Text] [Related]
13. RIPK1 activation mediates neuroinflammation and disease progression in multiple sclerosis.
Zelic M; Pontarelli F; Woodworth L; Zhu C; Mahan A; Ren Y; LaMorte M; Gruber R; Keane A; Loring P; Guo L; Xia TH; Zhang B; Orning P; Lien E; Degterev A; Hammond T; Ofengeim D
Cell Rep; 2021 May; 35(6):109112. PubMed ID: 33979622
[TBL] [Abstract][Full Text] [Related]
14. Discovery, optimization and evaluation of isothiazolo[5,4-b]pyridine derivatives as RIPK1 inhibitors with potent in vivo anti-SIRS activity.
Hao Y; Yang C; Shu C; Li Z; Xia K; Wu S; Ma H; Tian S; Ji Y; Li J; He S; Zhang X
Bioorg Chem; 2022 Dec; 129():106051. PubMed ID: 36115309
[TBL] [Abstract][Full Text] [Related]
15. Identification of an antibody-based immunoassay for measuring direct target binding of RIPK1 inhibitors in cells and tissues.
Finger JN; Brusq JM; Campobasso N; Cook MN; Deutsch J; Haag H; Harris PA; Jenkins EL; Joglekar D; Lich JD; Maguire S; Nagilla R; Rivera EJ; Sun H; Votta BJ; Bertin J; Gough PJ
Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226625
[TBL] [Abstract][Full Text] [Related]
16. A novel gut-restricted RIPK1 inhibitor, SZ-15, ameliorates DSS-induced ulcerative colitis.
Zeng YS; Peng J; Gao XF; Tian D; Zhan W; Liu J; Hu XJ; Huang S; Tian ST; Qiu L; Liang AL; Wang FY; Dong RH; Guang B; Yang T
Eur J Pharmacol; 2022 Dec; 937():175381. PubMed ID: 36368417
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors Targeting RIPK1/RIPK3: Old and New Drugs.
Martens S; Hofmans S; Declercq W; Augustyns K; Vandenabeele P
Trends Pharmacol Sci; 2020 Mar; 41(3):209-224. PubMed ID: 32035657
[TBL] [Abstract][Full Text] [Related]
18. A RIPK1-regulated inflammatory microglial state in amyotrophic lateral sclerosis.
Mifflin L; Hu Z; Dufort C; Hession CC; Walker AJ; Niu K; Zhu H; Liu N; Liu JS; Levin JZ; Stevens B; Yuan J; Zou C
Proc Natl Acad Sci U S A; 2021 Mar; 118(13):. PubMed ID: 33766915
[TBL] [Abstract][Full Text] [Related]
19. Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1.
Najjar M; Suebsuwong C; Ray SS; Thapa RJ; Maki JL; Nogusa S; Shah S; Saleh D; Gough PJ; Bertin J; Yuan J; Balachandran S; Cuny GD; Degterev A
Cell Rep; 2015 Mar; 10(11):1850-60. PubMed ID: 25801024
[TBL] [Abstract][Full Text] [Related]
20. When PERK inhibitors turn out to be new potent RIPK1 inhibitors: critical issues on the specificity and use of GSK2606414 and GSK2656157.
Rojas-Rivera D; Delvaeye T; Roelandt R; Nerinckx W; Augustyns K; Vandenabeele P; Bertrand MJM
Cell Death Differ; 2017 Jun; 24(6):1100-1110. PubMed ID: 28452996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
